z-logo
open-access-imgOpen Access
KL-6 as a Biomarker of Interstitial Lung Disease Development in Patients with Sjögren Syndrome: A Retrospective Case–Control Study
Author(s) -
Yu-Hsiang Chiu,
ChenChih Chu,
ChunChi Lu,
FengCheng Liu,
Shin-En Tang,
Shi-Jye Chu,
Shih-Ming Kuo,
Chen Hc
Publication year - 2022
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s352085
Subject(s) - medicine , interstitial lung disease , biomarker , gastroenterology , immunoassay , lung , antibody , immunology , biochemistry , chemistry
Krebs von den Lungen-6 (KL-6) is expressed on regenerating type II pneumocytes and has been recognized as biomarkers in interstitial lung disease (ILD). We aim to identify the role of the serum KL-6 level in patients with newly diagnosed Sjögren syndrome (SS), as well as the correlation between the immunoassays.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here